ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer

 

Study Summary

The purpose of the phase 3, clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.

Principal Investigator:

 

Phase

 

  • III

 

ClickForCTG

If you have any questions regarding this study or think that you or your loved one may be eligible, please feel free to contact:  
Julianne Wilson, MSN @ 908-237-2330 ex 2.

 

Menu